Abstract 166P
Background
An estimated 841,000 new Hepatocellular Carcinoma (HCC) cases have been identified globally, with Asia having the highest incidence (73%). However, there is limited real world data on how HCC is diagnosed and on the preferred treatment modalities. This study aims to evaluate and compare the presentation and management patterns in patients with HCC across Hong Kong (HK), Singapore (SG) and Thailand (TH).
Methods
Primary research was conducted amongst key HCC therapeutic area experts within Asia Pacific. A total of 18 oncologists, hepatologists and gastrointestinal specialists (6 HK; 6 SG; 6 TH) participated in the qualitative phase and a total of 55 (15 HK; 20 SG; 20 TH) in the quantitative phase. Face-to-face interviews using a discussion guide (Qualitative phase) were conducted in August to October 2019 and structured questionnaires (Quantitative phase) were implemented in October to November 2019. We are presenting the descriptive statistics of the stage at diagnosis, comorbidities and treatment modalities of HCC patients based upon this study.
Results
The key therapeutic area experts reported that patients in Hong Kong and Singapore present at an advanced stage per the Barcelona Clinic Liver Cancer (BCLC) guidelines (Stage C: 76% HK; 63% SG; 45% TH) as compared to patients in Thailand. Cirrhosis was a key etiology in Singapore and Thailand (90%, 77%) and Hepatitis B in Hong Kong (89%). Targeted therapy was the preferred first-line HCC treatment in Hong Kong, Singapore and Thailand (89%, 84%, 88%). Immunotherapy was the preferred second-line HCC treatment in Hong Kong (64%). Chemotherapy was used first-line in Thailand (13%) and second-line in Hong Kong, Singapore and Thailand (3%, 11%, 24%).
Conclusions
The treatment patterns and presentation of HCC patients at diagnosis varies considerably across Hong Kong, Singapore and Thailand. These findings on real world practice will be useful to clinicians in understanding the trends and patterns in the diagnosis of HCC and developing treatment strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kantar.
Funding
IPSEN Pharmaceutical company.
Disclosure
P.K.H. Chow: Advisory/Consultancy: Sirtex Medical; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Oncosil; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: MSD; Advisory/Consultancy: Roche. J-F. Baladi, Y. Chia, B. Ramaswamy: Full/Part-time employment: Ipsen. V. Grillo, A. Acorda, K. Xu, S. Singh, Y. Chen, Y. Gilliam, R. Gowindah: Full/Part-time employment: Kantar.
Resources from the same session
424P - Hippocampus sparing in volumetric modulated arc therapy (VMAT) for brain tumour radiotherapy treatment
Presenter: Eva Yi Wah Cheung
Session: e-Poster Display Session
425P - The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents
Presenter: Chun Loo Gan
Session: e-Poster Display Session
426P - A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg
Presenter: Marcia S. Brose
Session: e-Poster Display Session
427P - On the clinical implications of systemic and local immune responses in human angiosarcoma
Presenter: Jason Yongsheng Chan
Session: e-Poster Display Session
428P - Prognostic value of clinico-pathological characteristics and peripheral monocyte counts in localised extra-meningeal solitary fibrous tumours treated with surgical resection
Presenter: Ryan Lim
Session: e-Poster Display Session
429P - Demographics, pattern of care, and outcome analysis of malignant melanoma cases from a tertiary care centre in India
Presenter: Anshul Agarwal
Session: e-Poster Display Session
430P - Teenagers and young adult cancers in rural central India: Access to age-appropriate care
Presenter: Runu Sharma
Session: e-Poster Display Session
431P - Quantitative study of two critical lncRNAs in patients with glioma tumours
Presenter: Kamal Mohammadian
Session: e-Poster Display Session
432P - Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma
Presenter: Mustafa Gürbüz
Session: e-Poster Display Session
433P - Association between aspirin and cancer risk: A Mendelian randomization analysis
Presenter: Yu Jiang
Session: e-Poster Display Session